Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen (NASDAQ: AMGN) announced on Jan 6, 2026 the acquisition of Dark Blue Therapeutics for up to $840 million. The deal adds an investigational small molecule that targets and degrades proteins MLLT1/3, aimed at specific types of acute myeloid leukemia (AML).
Preclinical leukemia models showed promising anti-cancer activity and a mechanism differentiated from current therapies, supporting potential single-agent and combination use to address treatment resistance and durability of remission. Amgen said it will integrate Dark Blue into its research organization to strengthen early oncology discovery and advance the program toward clinical investigation.
Amgen (NASDAQ:AMGN) said it is taking action with the U.S. government to lower medicine costs for American patients while reaffirming investment in U.S. innovation and manufacturing.
Key moves: AmgenNow™ will add Aimovig and Amjevita at a discounted monthly price of $299 (about 60% and 80% below current U.S. list prices); Repatha was made available in October 2025 at $239 monthly. Amgen reported > $40 billion invested in U.S. manufacturing and R&D since 2018 and announced an additional $2.5 billion in U.S. manufacturing investments in 2025, including $900 million in Ohio and $1 billion in North Carolina. Amgen will receive industry tariff relief for the next three years.
Amgen (NASDAQ:AMGN) announced FDA approval of UPLIZNA (inebilizumab-cdon) on December 11, 2025 for treatment of adults with generalized myasthenia gravis (gMG) who are anti-AChR and anti-MuSK antibody positive.
Approval is supported by the Phase 3 MINT trial showing durable symptom control (MG-ADL difference at Week 26: -4.2 vs -2.2, 1.9-point treatment effect; AChR+ exploratory Week 52 difference: 2.8 points). UPLIZNA is the first CD19-targeted B cell therapy approved for these gMG subtypes, dosed twice yearly after two loading doses. Most common adverse reactions were headache and infusion-related reactions. UPLIZNA is Amgen's third indication after June 2020 and April 2025 approvals.
Amgen (NASDAQ:AMGN) announced a $2.52 per share dividend for Q1 2026. The Board declared the dividend on Dec 9, 2025, with a record date of February 13, 2026 and a payment date of March 6, 2026.
This dividend applies to all stockholders of record as of the close of business on the record date.
Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference on December 3, 2025 at 1:45 p.m. ET.
Presenters are Peter Griffith, executive vice president and chief financial officer, and Jay Bradner, executive vice president of Research and Development. The presentation will be webcast live and available to media, investors and the public on Amgen's investor website, with the webcast archived for replay for at least 90 days.
Amgen (NASDAQ:AMGN) will present at the 8th annual Evercore ISI HealthCONx Conference on December 3, 2025 at 10:00 a.m. ET. Presenters are Peter Griffith, executive vice president and chief financial officer, and Jay Bradner, executive vice president of Research and Development.
The presentation will be webcast live and available to the media, investors and the public via Amgen's investor website. Webcast details and links appear on Amgen's Investor Relations Events Calendar, and the archived replay will be available for at least 90 days after the event.
Amgen (NASDAQ: AMGN) announced that the FDA granted full approval to IMDELLTRA (tarlatamab-dlle) on Nov 19, 2025 for adult patients with extensive stage small cell lung cancer (ES-SCLC) with progression after platinum-based chemotherapy. The decision converts prior accelerated approval based on the global Phase 3 DeLLphi-304 trial, which showed a 40% reduction in risk of death versus standard chemotherapy (median overall survival 13.6 vs. 8.3 months; HR 0.60; P < 0.001).
The NCCN Guidelines were updated to list tarlatamab as the only Category 1 preferred option in this setting. Safety in DeLLphi-304 was consistent with known profile: fewer Grade ≥3 adverse events versus chemotherapy (54% vs. 80%); common IMDELLTRA toxicities included neutropenia (4%), lymphopenia (4%), and primarily low-grade cytokine release syndrome.
Amgen (NASDAQ:AMGN) reported Phase 3 VESALIUS-CV results showing Repatha (evolocumab) reduced first major adverse cardiovascular events by 25% (3‑P MACE) in >12,000 high‑risk adults without prior heart attack or stroke when added to LDL‑lowering therapy.
The trial also showed a 36% reduction in heart attack, a 19% reduction in 4‑P MACE, and median achieved LDL‑C of 45 mg/dL versus 109 mg/dL for placebo. No new safety signals were identified. Results presented at AHA 2025 and published in NEJM.
Amgen (NASDAQ:AMGN) reported Q3 2025 revenues of $9.6 billion, up 12% year-over-year, with product sales also up 12% driven by 14% volume growth and a 4% decline in net selling price. GAAP EPS rose 14% to $5.93; non-GAAP EPS was $5.64. GAAP operating margin improved to 27.6% while non-GAAP margin fell to 47.1%. The company generated $4.2 billion free cash flow in Q3 and retired $1.6 billion of debt in the quarter ($6.0 billion YTD). Management reiterated full-year 2025 guidance: revenues $35.8B–$36.6B, GAAP EPS $13.76–$14.60, non-GAAP EPS $20.60–$21.40.
Amgen (NASDAQ:AMGN) announced its 2025 fourth-quarter dividend: a cash dividend of $2.38 per share. The Board declared the dividend on Oct 31, 2025, with payment on December 12, 2025 to shareholders of record as of the close of business on November 21, 2025.